Details of the Drug
General Information of Drug (ID: DM7V8DZ)
| Drug Name |
Ribose-1-Phosphate
|
||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Synonyms |
ribose 1-phosphate; ribose-1-phosphate; alpha-D-Ribose 1-phosphate; CHEBI:16300; 1-O-phosphono-alpha-D-ribofuranose; alpha-D-ribofuranose 1-(dihydrogen phosphate); D-ribose-1-phosphate; alpha-D-ribose-1-phosphate; alpha-D-ribofuranose 1-phosphate; R1P; D-ribofuranose 1-(dihydrogen phosphate); 14075-00-4; D-ribose-1P; ribofuranose 1-phosphate; a-D-ribose 1-phosphate; D-ribofuranose 1-phosphate; alpha-D-Ribofuranose, 1-(dihydrogen phosphate); 1-phospho-alpha-D-ribofuranose; CHEMBL603367; SCHEMBL1995711; AC1L96Y2
|
||||||||||||||||||
| Indication |
|
||||||||||||||||||
| Drug Type |
Small molecular drug
|
||||||||||||||||||
| Structure |
![]() |
||||||||||||||||||
| 3D MOL | 2D MOL | ||||||||||||||||||
| #Ro5 Violations (Lipinski): 1 | Molecular Weight (mw) | 230.11 | |||||||||||||||||
| Logarithm of the Partition Coefficient (xlogp) | -3.1 | ||||||||||||||||||
| Rotatable Bond Count (rotbonds) | 3 | ||||||||||||||||||
| Hydrogen Bond Donor Count (hbonddonor) | 5 | ||||||||||||||||||
| Hydrogen Bond Acceptor Count (hbondacc) | 8 | ||||||||||||||||||
| Chemical Identifiers |
|
||||||||||||||||||
| Cross-matching ID | |||||||||||||||||||
| Drug-Molecule Activity Atlas (DMA)NEW | Click to Jump to the Detailed DMA Information of This Drug | ||||||||||||||||||
Molecular Interaction Atlas of This Drug
![]() Drug Therapeutic Target (DTT) |
|
||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Molecular Interaction Atlas (MIA) | |||||||||||||||||||||
Molecular Expression Atlas of This Drug
| The Studied Disease | Discovery agent | |||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ICD Disease Classification | N.A. | |||||||||||||||||
|
||||||||||||||||||
| Molecular Expression Atlas (MEA) | ||||||||||||||||||


